Phathom Pharmaceuticals Stock Surges on Strong Quarterly Performance

Phathom Pharmaceuticals is demonstrating remarkable momentum in the market, fueled by unexpectedly robust quarterly earnings and significant clinical development milestones. The biotechnology firm has surpassed analyst projections, establishing a definitive upward trajectory for its shares.

Analyst Confidence and Market Position

Market experts maintain a bullish outlook on Phathom, with the consensus rating standing at “Moderate Buy.” The average price target of $20.67 suggests potential appreciation of 39% from the current trading level of $14.85. Even more optimistic is the median price target of $24.00, indicating substantial upside potential of approximately 62%.

Technical indicators reinforce this positive assessment. The equity is trading comfortably above its 50-day, 150-day, and 200-day moving averages. With a relative strength rating of 93.79, the stock is outperforming 94% of all market securities—clear evidence of company-specific positive catalysts. The declining short interest, which fell nearly 4%, further confirms improving investor sentiment. At a market valuation around $1 billion, Phathom continues to represent an intriguing opportunity within the biotech investment landscape.

Exceptional Quarterly Financial Results

The company’s third-quarter 2025 financial report delivered outstanding results across key metrics. Phathom recorded net revenue of $49.5 million, significantly exceeding consensus estimates of $47.03 million. Even more impressive was the earnings performance, with a loss per share of just ($0.15) compared to anticipated losses of ($0.30).

Should investors sell immediately? Or is it worth buying Phathom Pharmaceuticals?

Management has reinforced this strong performance with an upgraded full-year 2025 guidance range of $170 to $175 million. Simultaneously, cash operating expenses decreased dramatically by 43% compared to the previous quarter.

• Third-quarter revenue: $49.5 million (representing 25% sequential growth)
• Third-quarter EPS: ($0.15) versus expected ($0.30)
• Full-year 2025 forecast: $170-$175 million
• Cumulative VOQUEZNA prescriptions exceed 790,000

VOQUEZNA’s Expanding Market Presence

The company’s flagship product, VOQUEZNA, continues to drive substantial growth. The third quarter alone saw approximately 221,000 prescriptions filled. Beyond current commercial success, Phathom has initiated a Phase 2 clinical trial for eosinophilic esophagitis in early November—a strategic expansion into new therapeutic applications.

The critical question remains whether VOQUEZNA can achieve blockbuster status. The forthcoming 2027 topline results will be pivotal in determining the product’s commercial valuation and future potential.